Sarepta Therapeutics Inc
SRPT17.207USD
+0.157+0.92%
交易中 （美东）报价延迟15分钟
1.68B总市值
亏损市盈率 TTM
关于 Sarepta Therapeutics Inc 公司
Sarepta Therapeutics, Inc. 是一家商业阶段的生物制药公司。该公司致力于通过发现和开发针对核糖核酸 (RNA) 的疗法、基因疗法和其他用于治疗罕见疾病的基因治疗方式来帮助患者。该公司已开发了多种用于治疗杜氏肌营养不良症 (Duchenne) 的获批产品，并正在开发用于治疗一系列疾病和病症的潜在治疗候选药物，包括杜氏肌营养不良症、肢带型肌营养不良症 (LGMD) 和其他神经肌肉和中枢神经系统 (CNS) 相关疾病。该公司已开发并商业化了四种获批的杜氏肌营养不良症治疗产品：EXONDYS 51（eteplirsen）注射液（EXONDYS 51）、VYONDYS 53（golodirsen）注射液（VYONDYS 53）、AMONDYS 45（casimersen）注射液（AMONDYS 45）和ELEVIDYS。其产品线包括约40个处于不同发现、临床前和临床开发阶段的项目。
公司简介
公司代码SRPT
公司名称Sarepta Therapeutics Inc
上市日期Jun 04, 1997
CEOMr. Douglas S. (Doug) Ingram, Esq., J.D.
员工数量1372
证券类型Ordinary Share
年结日Jun 04
公司地址215 First Street
城市CAMBRIDGE
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编02142
电话16172744000
网址https://www.sarepta.com/
公司代码SRPT
上市日期Jun 04, 1997
CEOMr. Douglas S. (Doug) Ingram, Esq., J.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Richard J. (Rick) Barry
Mr. Richard J. (Rick) Barry
Independent Director
Independent Director
3.21M
+1.02%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Chief Executive Officer
Chief Executive Officer
390.31K
--
Dr. Louise Rodino-Klapac, Ph.D.
Dr. Louise Rodino-Klapac, Ph.D.
President - Research and Development and Technical Operations
President - Research and Development and Technical Operations
201.48K
+249.76%
Mr. Ian Michael Estepan
Mr. Ian Michael Estepan
President, Chief Operating Officer
President, Chief Operating Officer
189.46K
+315.61%
Mr. Ryan Wong
Mr. Ryan Wong
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
136.20K
+686.03%
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Independent Director
Independent Director
22.84K
-2.30%
Mr. Dallan Murray
Mr. Dallan Murray
Executive Vice President, Chief Customer Officer
Executive Vice President, Chief Customer Officer
21.18K
-44.29%
Ms. Cristin L. Rothfuss
Ms. Cristin L. Rothfuss
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
--
--
Ms. Deirdre Connelly
Ms. Deirdre Connelly
Independent Director
Independent Director
--
--
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Richard J. (Rick) Barry
Mr. Richard J. (Rick) Barry
Independent Director
Independent Director
3.21M
+1.02%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Chief Executive Officer
Chief Executive Officer
390.31K
--
Dr. Louise Rodino-Klapac, Ph.D.
Dr. Louise Rodino-Klapac, Ph.D.
President - Research and Development and Technical Operations
President - Research and Development and Technical Operations
201.48K
+249.76%
Mr. Ian Michael Estepan
Mr. Ian Michael Estepan
President, Chief Operating Officer
President, Chief Operating Officer
189.46K
+315.61%
Mr. Ryan Wong
Mr. Ryan Wong
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
136.20K
+686.03%
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Independent Director
Independent Director
22.84K
-2.30%
收入明细
单位: USD更新时间: 7月6日 周日
单位: USD更新时间: 7月6日 周日
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
业务USD
名称
营收
占比
ELEVIDYS
374.99M
50.34%
PMO Products
236.54M
31.76%
collaboration and other
133.33M
17.90%
地区USD
名称
营收
占比
United States
560.81M
75.29%
Rest of World
50.71M
6.81%
业务
地区
业务USD
名称
营收
占比
ELEVIDYS
374.99M
50.34%
PMO Products
236.54M
31.76%
collaboration and other
133.33M
17.90%
股东统计
更新时间: 8月16日 周六
更新时间: 8月16日 周六
持股股东
股东类型
持股股东
持股股东
占比
The Vanguard Group, Inc.
10.17%
BlackRock Institutional Trust Company, N.A.
9.40%
D. E. Shaw & Co., L.P.
4.83%
State Street Global Advisors (US)
4.49%
Two Sigma Investments, LP
3.96%
其他
67.15%
持股股东
持股股东
占比
The Vanguard Group, Inc.
10.17%
BlackRock Institutional Trust Company, N.A.
9.40%
D. E. Shaw & Co., L.P.
4.83%
State Street Global Advisors (US)
4.49%
Two Sigma Investments, LP
3.96%
其他
67.15%
股东类型
持股股东
占比
Investment Advisor
32.82%
Investment Advisor/Hedge Fund
20.56%
Hedge Fund
20.02%
Research Firm
5.08%
Individual Investor
4.67%
Bank and Trust
1.23%
Pension Fund
1.17%
Sovereign Wealth Fund
0.90%
Insurance Company
0.03%
其他
13.52%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
1032
95.91M
98.15%
-10.95M
2025Q1
1077
102.36M
104.40%
-6.43M
2024Q4
1057
102.62M
105.91%
-1.51M
2024Q3
1027
96.14M
100.83%
-6.90M
2024Q2
997
94.21M
99.66%
-1.44M
2024Q1
932
88.31M
94.10%
-6.68M
2023Q4
926
87.42M
93.47%
-6.42M
2023Q3
916
88.86M
95.27%
-4.43M
2023Q2
931
87.46M
93.91%
-4.38M
2023Q1
946
86.41M
92.84%
-2.26M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
9.01M
9.17%
-59.02K
-0.65%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
8.90M
9.06%
-32.03K
-0.36%
Mar 31, 2025
State Street Global Advisors (US)
4.07M
4.14%
-1.39K
-0.03%
Mar 31, 2025
Barry (Richard J)
3.21M
3.27%
+32.60K
+1.02%
May 16, 2025
Wellington Management Company, LLP
2.65M
2.69%
+577.85K
+27.93%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.82M
1.85%
+114.57K
+6.71%
Mar 31, 2025
Erste Asset Management GmbH
1.06M
1.08%
+352.82K
+49.82%
Mar 31, 2025
查看更多
持股ETF
更新时间: 9月6日 周六
更新时间: 9月6日 周六
机构名称
占比
iShares Core S&P U.S. Value ETF
0%
iShares Core S&P U.S. Value ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
